美国埃默里大学Ignacio Sanz、F. Eun-Hyung Lee等研究人员合作发现，滤泡外B细胞反应与中和抗体和COVID-19发病率相关。相关论文于2020年10月7日在线发表于国际学术期刊《自然—免疫学》。
Title: Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19
Author: Matthew C. Woodruff, Richard P. Ramonell, Doan C. Nguyen, Kevin S. Cashman, Ankur Singh Saini, Natalie S. Haddad, Ariel M. Ley, Shuya Kyu, J. Christina Howell, Tugba Ozturk, Saeyun Lee, Naveenchandra Suryadevara, James Brett Case, Regina Bugrovsky, Weirong Chen, Jacob Estrada, Andrea Morrison-Porter, Andrew Derrico, Fabliha A. Anam, Monika Sharma, Henry M. Wu, Sang N. Le, Scott A. Jenks, Christopher M. Tipton, Bashar Staitieh, John L. Daiss, Eliver Ghosn, Michael S. Diamond, Robert H. Carnahan, James E. Crowe, William T. Hu, F. Eun-Hyung Lee, Ignacio Sanz
Abstract: A wide spectrum of clinical manifestations has become a hallmark of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic, although the immunological underpinnings of diverse disease outcomes remain to be defined. We performed detailed characterization of B cell responses through high-dimensional flow cytometry to reveal substantial heterogeneity in both effector and immature populations. More notably, critically ill patients displayed hallmarks of extrafollicular B cell activation and shared B cell repertoire features previously described in autoimmune settings. Extrafollicular activation correlated strongly with large antibody-secreting cell expansion and early production of high concentrations of SARS-CoV-2-specific neutralizing antibodies. Yet, these patients had severe disease with elevated inflammatory biomarkers, multiorgan failure and death. Overall, these findings strongly suggest a pathogenic role for immune activation in subsets of patients with COVID-19. Our study provides further evidence that targeted immunomodulatory therapy may be beneficial in specific patient subpopulations and can be informed by careful immune profiling.